Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.

[1]  S. Hori,et al.  Transcatheter Arterial Chemoembolization with Epirubicin-Loaded Superabsorbent Polymer Microspheres for 135 Hepatocellular Carcinoma Patients: Single-Center Experience , 2011, CardioVascular and Interventional Radiology.

[2]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[3]  L. Schwartz,et al.  Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Y. Takikawa,et al.  Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma. , 2010, World journal of gastroenterology.

[5]  J. Bruix,et al.  Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (SPACE). , 2010 .

[6]  J. Kao,et al.  Prevention of hepatocellular carcinoma in the Asia–Pacific region: Consensus statements , 2010, Journal of gastroenterology and hepatology.

[7]  M. Kudo.  The 2008 Okuda lecture: Management of hepatocellular carcinoma: From surveillance to molecular targeted therapy , 2010, Journal of gastroenterology and hepatology.

[8]  Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire.  A Comparison of Lipiodol Chemoembolization and Conservative Treatment for Unresectable Hepatocellular Carcinoma , 2009 .

[9]  G. Gores,et al.  Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis , 2009, British Journal of Cancer.

[10]  Jin-Lin Hou,et al.  Hepatocellular carcinoma in the Asia pacific region , 2009, Journal of gastroenterology and hepatology.

[11]  Jaume Bosch,et al.  Angiogenesis in liver disease. , 2009, Journal of hepatology.

[12]  J. H. Kim,et al.  Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients , 2008, Cancer science.

[13]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[14]  E. Cholongitas,et al.  Transarterial Therapy for Hepatocellular Carcinoma: Which Technique Is More Effective? A Systematic Review of Cohort and Randomized Studies , 2007, CardioVascular and Interventional Radiology.

[15]  M. Makuuchi,et al.  Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. , 2006, Gastroenterology.

[16]  M. Santoro,et al.  BAY 43-9006 inhibition of oncogenic RET mutants. , 2006, Journal of the National Cancer Institute.

[17]  M. Makuuchi,et al.  Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. , 2006, World journal of gastroenterology.

[18]  Dong Chen,et al.  The value and limitation of transcatheter arterial chemoembolization in preventing recurrence of resected hepatocellular carcinoma. , 2005, World journal of gastroenterology.

[19]  J. Llovet,et al.  Updated treatment approach to hepatocellular carcinoma , 2005, Journal of Gastroenterology.

[20]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[21]  C. Zheng,et al.  Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. , 2004, World journal of gastroenterology.

[22]  A. Burroughs,et al.  Hepatocellular carcinoma , 2003, The Lancet.

[23]  J. Bruix,et al.  Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival , 2003, Hepatology.

[24]  S. Wilhelm,et al.  BAY 43-9006: preclinical data. , 2002, Current pharmaceutical design.

[25]  Ramon Planas,et al.  Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial , 2002, The Lancet.

[26]  John Wong,et al.  Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma , 2002, Hepatology.

[27]  M. Bernardi,et al.  Randomized Control Trials on Chemoembolization for Hepatocellular Carcinoma: Is There Room for New Studies? , 2001, Journal of clinical gastroenterology.

[28]  M. Yoshikawa,et al.  Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. , 2000, AJR. American journal of roentgenology.

[29]  R. Yamada,et al.  Hepatic artery embolization in 120 patients with unresectable hepatoma. , 1983, Radiology.

[30]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[31]  Bin Wang,et al.  Increased Expression of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization , 2008 .

[32]  S. Chevret,et al.  A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. , 1995, The New England journal of medicine.

[33]  R. Yamada,et al.  Hepatic artery embolization in 32 patients with unresectable hepatoma. , 1980, Osaka city medical journal.